Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2020 Jan 15;521(3):549-554. doi: 10.1016/j.bbrc.2019.09.097. Epub 2019 Oct 31.

Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13.

Author information

1
Department of Neuroscience, IRBM S.p.A, Via Pontina Km 30.600, 00071, Pomezia, Rome, Italy.
2
Peptide Chemistry Unit, IRBM S.p.A., Via Pontina Km 30 600, 00071, Pomezia, Rome, Italy.
3
Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, Station 19, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015, Lausanne, Switzerland.
4
CHDI Management/CHDI Foundation, Los Angeles, CA, 90045, USA.
5
CHDI Management/CHDI Foundation, Princeton, NJ 08540, USA. Electronic address: ramee.lee@chdifoundation.org.
6
CHDI Management/CHDI Foundation, Princeton, NJ 08540, USA.

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder caused by an expansion of a CAG triplet repeat (encoding for a polyglutamine tract) within the first exon of the huntingtin gene. Expression of the mutant huntingtin (mHTT) protein can result in the production of N-terminal fragments with a robust propensity to form oligomers and aggregates, which may be causally associated with HD pathology. Several lines of evidence indicate that N17 phosphorylation or pseudophosphorylation at any of the residues T3, S13 or S16, alone or in combination, modulates mHTT aggregation, subcellular localization and toxicity. Consequently, increasing N17 phosphorylation has been proposed as a potential therapeutic approach. However, developing genetic/pharmacological tools to quantify these phosphorylation events is necessary in order to subsequently develop tool modulators, which is difficult given the transient and incompletely penetrant nature of such post-translational modifications. Here we describe the first ultrasensitive sandwich immunoassay that quantifies HTT phosphorylated at residue S13 and demonstrate its utility for specific analyte detection in preclinical models of HD.

KEYWORDS:

Huntington’s disease; Immunoassay; Neurodegeneration; Phosphorylation; Post-translational modifications

PMID:
31677786
DOI:
10.1016/j.bbrc.2019.09.097

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center